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Abstract: Milnacipran is a serotonin and norepinephrine reuptake inhibitor (SNRI), with a 
balanced potency for the inhibition of the reuptake of the two monoamines. In this, it contrasts 
with venlafaxine and duloxetine which, while possessing a dual action, have a selectivity of 
the order of 30-fold and 10-fold respectively for the reuptake of serotonin. Milnacipran has 
mainly been launched in countries where the selective serotonin reuptake inhibitors (SSRIs) and 
venlafaxine had been established for several years. As such it has attracted relative little interest 
from clinician investigators as a research tool. Japan, however, represents a unique situation 
because in 1999 milnacipran was launched within months of the ﬁ  rst SSRI and is still the only 
SNRI in Japan together with only two SSRIs (a third has just been introduced). This has led to 
a large number of investigative clinical studies, many of which give interesting insights into 
the potential of milnacipran in the treatment of depression and of other disorders. This article 
reviews these Japanese studies with milnacipran.
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Introduction
The treatment of depression in Japan
“Life means suffering” is the ﬁ  rst of the four noble truths of Buddhism and for over 
15 centuries this religion/philosophy has encouraged the acceptance of suffering and 
sadness and discouraged the pursuit of happiness. In Japanese mythology stories rarely 
have “a happy ending” while sadness and suffering are both noble and omnipresent. 
This may go some way to explaining why mental illness has never been adequately 
addressed in Japan.
The Japanese word for depression, “utsubyo,” traditionally refers only to severe 
or bipolar depression. In fact, until recently, depression was considered in the same 
way as schizophrenia, and treated only in specialized institutions.
Although there are no nationwide epidemiological data for depression in Japan, 
a small-scale survey found that, based on the Center for Epidemiological Studies 
Depression (CES-D) criteria, 13% of men and 16% of women had depressive 
symptomatology with 4.5% and 9.4%, respectively, having moderate or severe 
depressive symptoms (Miyaji et al 1994). Another small survey (Kawakami et al 
1996), using the DSMIII-R (Diagnostic and Statistical Manual of Mental Disorders, 
Third Edition, Revised) criteria in a cohort of 140 Japanese workers found 6-
month and lifetime prevalence rates of major depressive episodes to be 4% and 
14%, respectively. More recently the World Mental Health Japan Survey made 
a 12-month survey (2002–2003) of 1663 persons from four areas (two urban and 
two rural) of Japan (Kawakami et al 2005). Using the World Health Organization 
Composite International Diagnostic Interview (WMH-CIDI) the survey found a 12-
month prevalence of major depression of only 2.9%. Both of these studies suggest Neuropsychiatric Disease and Treatment 2007:3(1) 42
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a prevalence considerably lower than in Western countries 
where the Depression Research in European Society study 
(DEPRES) found a 6-month prevalence of 17% (Lepine 
et al 1997). Another survey in Japan (Kawakami et al 2004), 
which also found a relatively low incidence of depression 
in a sample of 1029 urban Japanese, observed a greater risk 
of mood, anxiety, and alcohol use disorders among a recent 
birth cohort. Whether this reﬂ  ects a change in prevalence 
of depression in the younger generation in Japan remains 
to be seen. A sign that the traditional view of depression as 
being rare in Japan may not be the whole story is the fact that 
Japan’s suicide rate is one of the highest in the world, more 
than three times that of the UK, for example, and continues 
to increase each year (World Health Organization data).
In view of the traditional Japanese attitude to depression, it 
is not surprising that until recently, sales of antidepressants in 
Japan were minimal. Total annual sales of all antidepressants 
in Japan (population 125 million) in 1995 were just over 
US$150 million compared with more than US$2 billion in 
sales of ﬂ  uoxetine alone in the USA (population 300 million) 
the same year. At that time only tricyclic antidepressants 
(TCAs) and a few “atypical” antidepressants such as 
mianserin were available in Japan.
In 1999 ﬂ  uvoxamine was introduced into Japan as the ﬁ  rst 
“modern” antidepressant. This selective serotonin reuptake 
inhibitor (SSRI) was rapidly followed by the serotonin (5-
HT) and norepinephrine (NE) reuptake inhibitor (SNRI) 
milnacipran, and a second SSRI, paroxetine. These three 
remained the only “modern” antidepressants until July 2006 
when sertraline was launched, ironically on the same day 
that it became generic in the USA. Escitalopram/citalopram, 
ﬂ  uoxetine, venlafaxine, mirtazapine, and duloxetine are either 
still under development in Japan or have been “abandoned” 
for the Japanese market.
The introduction of the three “modern” antidepressants 
was accompanied by considerable effort to increase medical 
and public awareness of depression with a three-point 
message:
1.  Depression is a disease from which anyone can suffer.
2.  It can be successfully treated with drugs.
3.  Early detection and the treatment of “mild” depressive  
  symptoms improve prognosis.
Since the introduction of the three “modern” antidepres-
sants in 1999/2000 the antidepressant market has expanded 
more than four-fold to US$650 million in 2005. Paroxetine 
is the clear market leader with approximately 50% of the 
market. The SNRI milnacipran comes second with 12.5% 
of the market, followed by ﬂ  uvoxamine. Almost all of the 
increase in the antidepressant market is represented by sales 
of these three drugs.
Milnacipran in Japan—a unique situation
In Europe and elsewhere milnacipran has been systematically 
launched on a market where the SSRIs have been established 
for a number of years and where venlafaxine is usually 
the “reference SNRI.” In Japan, however, milnacipran 
was launched within months of the ﬁ  rst SSRI and is the 
only SNRI present on the Japanese market. In addition 
to the obvious commercial advantage of this situation, 
Japanese clinicians, who had been deprived of modern 
antidepressants for many years, ﬁ  nally had both SSRI and 
SNRI drugs to use and to investigate clinically. This has 
led to a large number of studies, most of them preliminary, 
many of which give interesting insights on the potential 
of milnacipran in the treatment of depression and of other 
disorders. This article will review these Japanese studies 
with milnacipran.
An extensive Medline search was carried out using 
“milnacipran” as a keyword and all publications by Japanese 
authors (based on the address given in the publications) were 
retained. Following our request, Pierre Fabre Médicament, 
manufacturers of milnacipran, and Asahi-Kasei, who sell 
milnacipran in Japan, supplied additional references. All 
original publications were retained for inclusion in this 
review. Articles in Japanese were only included where a 
substantial English language summary was available. No 
“qualitative” assessment of the publications was made.
Basic studies
Although a lot of basic studies had already been carried out 
before milnacipran was introduced onto the Japanese market 
(for review see Briley et al 1996), the subsequent enthusiasm 
of Japanese researchers has led to a number of signiﬁ  cant pre-
clinical contributions to our understanding of milnacipran.
Effects on monoamines and monoamine 
reuptake
The key characteristic of milnacipran, namely its equipotency 
for the inhibition of 5-HT and NE reuptake (Moret et al 1986), 
was conﬁ  rmed in Japanese preclinical studies (Mochizuki 
et al 2002a) which showed that milnacipran selectively 
inhibited sodium-dependent 5-HT and NE uptake into the 
rat cerebral cortex synaptosomes with similar potencies and 
no effect on any neurotransmitter receptor.Neuropsychiatric Disease and Treatment 2007:3(1) 43
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Microdialysis studies in the medial prefrontal cortex 
showed that milnacipran caused a dose-related increase in 
the extracellular levels of 5-HT and NE with similar potency 
(Mochizuki et al 2002a). These results were similar to those 
obtained previously in guinea pig hypothalamus (Moret 
and Briley 1997). Another microdialysis study in the cell 
body regions (Bandoh et al 2004) showed that a single 
administration of milnacipran decreased the levels of NE and 
its metabolite, 4-hydroxy-3-methoxymandelic acid, in the 
locus coeruleus, and the levels of 5-HT and its metabolite, 
5-hydroxyindole-3-acetic acid, in the dorsal raphe nucleus. 
Combined administration of milnacipran with either the α2-
adrenoceptor antagonist, yohimbine, or the 5-HT1A receptor 
antagonist, WAY100635, reversed the milnacipran-induced 
decreases of NE and 5-HT, respectively, indicating that 
treatment with milnacipran causes negative feedback through 
stimulation of α2-adrenoceptors and 5-HT1A autoreceptors in 
the cell-body regions.
Treatment with milnacipran for 7 days results in a 
significant increase in the basal levels of extracellular 
NE in the medial prefrontal cortex in rats (Kitaichi et al 
2005a). In addition acute administration of milnacipran 
following a 7-day treatment of milnacipran results in a 
greater increase in extracellular NE than a single acute 
administration of milnacipran alone. These results suggest 
that repeated milnacipran treatment enhances noradrenergic 
neuronal transmission beyond that achieved with acute 
administration alone. Interestingly, repeated administration 
of milnacipran had no effect on serotonergic or dopaminergic 
neurotransmission.
Cultured adrenal medullary cells have been used as 
an in vitro model for studying NE transporter function. In 
this model, prolonged exposure to milnacipran appears to 
increase NE transporter function (Shinkai et al 2005). As 
expected, an acute exposure with milnacipran resulted in 
a competitive inhibition of the NE transporter. Prolonged 
exposure with milnacipran, however, caused time- and 
concentration-dependent increases in NE uptake and NE 
transporter density with no increase in NE transporter mRNA. 
The addition of the ribosomal protein synthesis inhibitor, 
cycloheximide, abolished these effects (Shinkai et al 2005) 
suggesting that up-regulation of NE transporter function 
following prolonged exposure to milnacipran, probably 
results from post-transcriptional modiﬁ  cations.
In addition to neurons, glial cells have also been shown 
to express functional NE transporter sites and may exert 
signiﬁ  cant control of noradrenergic activity by inactivating 
NE that escapes neuronal re-uptake at sites distant from 
terminals (Henn and Hamburger 1971). Milnacipran has 
been shown to inhibit the reuptake of NE by cultured rat 
cortical astrocytes, an experimental model of glial cells 
(Inazu et al 2003) with characteristics similar to those of 
neuronal reuptake.
Electrophysiological studies
Repeated administration of milnacipran for at least 7 days 
has been found, using electrophysiological techniques, 
to signiﬁ  cantly attenuate the potency of 5-HT to inhibit 
the ﬁ  ring of serotonergic neurons in the raphe nucleus 
while inhibition of the CA1 ﬁ  eld potential by 5-HT in the 
hippocampus is not modiﬁ  ed (Mochizuki et al 2002b). This 
suggests that milnacipran rapidly desensitizes presynaptic 
somatodendritic 5-HT1A receptors but not postsynaptic 
5-HT1A receptors.
Similar studies on the noradrenergic system found 
that milnacipran hyperpolarizes locus coeruleus neurons 
and enhances the inhibitory postsynaptic potential by 
increasing endogenous NE at synapses within locus coeruleus 
(Kuwahata et al 2004).
Methylphenidate, which is used in the treatment 
of attention deficit/hyperactivity disorder (ADHD), is 
thought to act as an indirect NE and DA receptor agonist. 
The electrophysiological effects of methylphenidate and 
milnacipran have been compared (Kidani et al 2005). 
Both compounds produced a concentration-dependent 
hyperpolarizing response in locus coeruleus neurons, which 
blocked spontaneous ﬁ  ring of locus coeruleus neurons. 
The hyperpolarization was blocked by the α2-adrenoceptor 
antagonist, yohimbine, suggesting that it is mediated by 
NE acting on α2-adrenoceptors on locus coeruleus neurons. 
The similar results obtained with methylphenidate and 
milnacipran suggest that the antidepressant may be helpful 
in the treatment of attention deﬁ  cit hyperactivity disorder. 
This hypothesis has yet to be tested clinically.
TCAs are known to inhibit various ligand-gated ion-
channel (LGIC) receptors, and some of their clinical 
features may be associated with this activity. Ueta et al 
(2004) investigated whether this might also be the case with 
milnacipran. The two-voltage clamp technique was used to 
measure the in vitro effects of milnacipran on the activity on 
four recombinant LGIC receptors, nicotinic acetylcholine, 
N-methyl-D-aspartate, gamma-amino butyric acid (GABA), 
and 5-HT3A receptors expressed in Xenopus oocytes. 
Milnacipran showed no interaction at the GABA receptor Neuropsychiatric Disease and Treatment 2007:3(1) 44
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while the three other LGIC receptors were only inhibited 
by very high concentrations of milnacipran suggesting that, 
unlike the TCAs, under clinical conditions milnacipran has 
no signiﬁ  cant effects on these receptors.
Effects on brain plasticity
Changes in brain plasticity involve neuronal atrophy, 
neurogenesis, dendrite involution and formation, and long-
term potentiation (LTP), which is a form of synaptic plasticity 
that is thought to underlie learning and memory. These changes 
have been suggested to play a major role in the neurobiological 
basis of depression (Reid and Stewart 2001). Several studies 
carried out by Japanese researchers have investigated the role 
of milnacipran in changes in brain plasticity.
A single administration of milnacipran suppresses 
LTP in the hippocampal CA1 ﬁ  eld in rats (Tachibana et al 
2004), an effect which was reversed by pretreatment with 
the selective 5-HT1A receptor antagonist, WAY 100635, or 
the α1-adrenoceptor antagonist, prazosin, but not the α2-
adrenoceptor antagonist, idazoxan. Repeated treatment with 
milnacipran for 14 days, however, completely restored the 
suppression of LTP caused by single milnacipran treatment 
(Tachibana et al 2006). In addition, LTP suppression 
induced by the 5-HT1A receptor agonist, tandospirone, 
was also completely reversed by repeated treatment with 
milnacipran.
In a conditioned fear stress paradigm, rats that received 
foot-shock stimulation every day for 5 days were found, 
10 days later, to have increased freezing behavior. 
Electrophysiological studies in rats subjected to the same 
paradigm were found, after 10 days, to have suppressed LTP 
in the CA1 ﬁ  eld of the hippocampus. Chronic but not acute 
treatment with milnacipran reduced both freezing behavior 
and the suppressed LTP induced by conditioned fear stress 
(Matsumoto et al 2005).
Thus repeated administration of milnacipran is capable 
of restoring LTP suppressed by both drugs and behavioral 
techniques. Single and repeated administration of milnacipran 
increase extracellular NE in the hippocampus to a similar 
extent whereas the increased extracellular 5-HT resulting from 
a single administration of milnacipran is further enhanced by 
repeated treatment. This suggests that milnacipran-induced 
restoration of LTP following repeated exposure may be the 
result of enhanced 5-HT neurotransmission (Tachibana et al 
2006) rather than effect on the noradrenergic system.
Increasingly LTP is seen as a means of protection against 
the negative effects of stress and its restoration may be a 
common down-stream function in the treatment of disorders 
such as depression (Cooke and Bliss 2005).
Effects on the hypothalamic–pituitary–adrenal axis
Dysregulation of the hypothalamic–pituitary–adrenal 
(HPA) axis is widely considered to be implicated in the 
pathophysiology of depression. Antidepressant drugs have 
been suggested to exert their clinical action via a facilitation 
of glucocorticoid receptor gene expression and function in 
the HPA (Brady et al 1991). Milnacipran, in common with 
other antidepressants such as desipramine, clomipramine, 
ﬂ  uoxetine and clorgyline, has been shown to induce a rapid 
and sustained translocation of the glucocorticoid receptor 
into the nucleus of human lymphocytes in vitro (Okuyama-
Tamura et al 2003).
Effects in animal behavioral models
Animal behavioral models for depression and anxiety can 
be useful in orientating clinical research. Japanese studies 
(Mochizuki et al 2002a) have confirmed the effects of 
milnacipran in behavioral studies carried out in Europe 
(reviewed in Briley et al 1996). Milnacipran signiﬁ  cantly 
reduced the duration of both the immobility time in the forced 
swimming test (depression test) and the freezing time in the 
conditioned fear stress test (anxiety test) in rats.
Conditioned fear stress (CFS)-induced freezing behavior 
has been proposed as an animal model of anxiety especially 
social anxiety. CFS-induced freezing is attenuated by the acute 
administration of milnacipran as well as the SSRIs, citalopram 
and ﬂ  uvoxamine, whereas the selective NE reuptake inhibitor, 
maprotiline, was inactive (Hashimoto et al 1996). These 
results suggest an important role for the facilitation of 5-HT 
neurotransmission in the reduction of CFS-induced freezing 
behavior. A study in an analogous model in mice showed 
similar results with milnacipran and ﬂ  uvoxamine inhibiting 
conditioned fear stress induced freezing behavior to a similar 
extent (Miyamoto et al 2004).
The clinical efﬁ  cacy of ﬂ  uvoxamine in social anxiety 
disorder has been demonstrated by placebo controlled trials 
in the USA (Stein et al 1999), Europe (Westenberg et al 
2004) and Japan (Asakura et al 2006). In addition, results 
from open studies suggest that both milnacipran (Nagata et al 
2003, 2005) and ﬂ  uvoxamine (Matsunaga et al 2001) may be 
active in the treatment of Taijin Kyofusho: a speciﬁ  c Japanese 
form of social anxiety disorder (see below). Milnacipran is 
thus likely to be useful in the treatment of social anxiety 
disorder.Neuropsychiatric Disease and Treatment 2007:3(1) 45
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Milnacipran has been tested in a number of animal 
models of chronic pain (Mochizuki 2004). In a model of 
chronic pain based on the injection of formalin into the 
paw of a rodent, milnacipran and inhibitors of NE reuptake, 
such as nisoxetine, nortriptyline and maprotiline, produced 
potent anti-nociceptive effects, whereas SSRIs, such as 
ﬂ  uvoxamine, were much less potent. Another model involving 
ligation of the 5th spinal nerve induces behavioral signs in 
rats and mice that are similar to the symptoms of human 
neuropathic pain. In this model, the TCAs amitriptyline, a 
relatively non-selective 5-HT and NE reuptake blocker, and 
desipramine, a preferential NE reuptake inhibitor, and the 
SNRIs milnacipran and duloxetine, all signiﬁ  cantly decreased 
sensitivity to pain. The SSRI, ﬂ  uoxetine, however, was 
ineffective (Mochizuki 2004).
Using a rat model of neuropathic pain involving ligation 
of the left L5 and L6 spinal nerves, Obata et al (2005) 
showed that milnacipran injected directly into the spinal 
cord produced dose-dependent reduction in pain sensitivity 
which lasted for 7 hours. The intrathecal administration of 
paroxetine or maprotiline did not modify pain sensitivity. 
The reduction in pain sensitivity produced by milnacipran 
was attenuated by intrathecal co-administration of the α2-
adrenoceptor antagonist, yohimbine, or the 5-HT receptor 
antagonist, methysergide. These results suggest that 
antidepressants acting on both the noradrenergic and 
serotonergic systems are more effective than those acting 
on a single neurotransmitter system.
These positive ﬁ  ndings in animal models of chronic pain 
have stimulated considerable clinical interest and milnacipran 
has now been tested in a number of clinical situations of 
chronic pain (see below).
Human pharmacokinetics
Genetic polymorphisms of cytochrome P450 metabolic 
enzymes can have profound effects on the efﬁ  cacy and 
tolerance of drugs (see for example Mamiya et al 1998). 
Studies with Japanese human liver and intestinal microsomes 
(Tsuruta et al 2000) have shown that milnacipran does not 
inhibit CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, 
or CYP3A4 at clinically relevant concentrations. Phase I 
studies in Japan (unpublished) have shown that milnacipran 
is mainly excreted unchanged in urine, partly as a glucuronide 
conjugate and partly unchanged. The drug is only metabolized 
to a limited degree (less than 20%), principally to an inactive 
metabolite, N-desmethyl-milnacipran, by the action of 
CYP3A4 in the liver. These results are the same as those 
obtained in Europe (Puozzo and Leonard 1996) indicating 
that there is no reason to expect any racial differences in 
the properties of milnacipran based on differences in its 
pharmacokinetic characteristics.
Clinical studies
Double-blind randomized clinical 
trials in Japan
Early Japanese clinical experience with milnacipran has 
been reviewed previously (Mimura 2001; Tajima 2002). 
There have been few randomized clinical trials carried out 
in Japan. One of the ﬁ  rst was a double-blind, parallel-group 
trial comparing treatment with milnacipran and imipramine 
(Yamashita et al 1995) in 127 depressed patients. The patient 
population was comparable to that included in the European 
comparative studies (Kasper et al 1996). Treatment with 
both imipramine and milnacipran was started at 50 mg/d 
(25 mg twice daily) for the ﬁ  rst week and then increased 
ﬂ  exibly up to a maximum of 150 mg/d. Mean ﬁ  nal dose 
administered was 77 mg/d for milnacipran and 89 mg/d for 
imipramine. Depressive symptoms improved progressively in 
both groups. After the ﬁ  rst week signiﬁ  cantly more patients 
(53.2%) in the milnacipran group were considered to be 
“moderately” or “substantially” improved compared to those 
in the imipramine group (18.8%) (p = 0.029). At the end of the 
study, however, there was no signiﬁ  cant difference between 
treatments with 58% of patients in the milnacipran group and 
56% in the imipramine group considered “moderately” or 
“substantially” improved.
Another double-blind, parallel-group study compared 
milnacipran and mianserin in 178 patients (Endo et al 1995). 
Patients received either milnacipran 50 mg/d (25 mg twice 
daily) or mianserin 30 mg/d (15 mg twice daily) for the 
ﬁ  rst week. The dose could then be increased to a maximum 
of 100 mg/d milnacipran or 60 mg/d mianserin. The mean 
ﬁ  nal doses of milnacipran and mianserin were 75 mg/d and 
43 mg/d, respectively. At the end of the 4-week treatment 
period, 40% and 37% of patients were considered to be 
“moderately” or “substantially” improved in the milnacipran 
and mianserin treatment groups respectively. There was no 
signiﬁ  cant difference between treatments.
These studies show the non-inferiority of the antidepressant 
efﬁ  cacy of milnacipran as compared to the principal reference 
antidepressants used in Japan at that time.
The adverse events reported for milnacipran in the 
comparative study with imipramine in Japan were similar Neuropsychiatric Disease and Treatment 2007:3(1) 46
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in nature and frequency to those seen in European studies 
(Kasper et al 1996). Interestingly, the adverse events proﬁ  le 
seen with milnacipran in the imipramine study differed 
considerably from that seen in the mianserin study (Table 1). 
For example, dry mouth and constipation were much more 
frequent with milnacipran in the imipramine study than in the 
mianserin study, whilst the opposite was true for drowsiness. 
Dry mouth and drowsiness are known and expected side-
effects of imipramine and mianserin respectively. Expected 
side-effects were probably sought more conscientiously, and 
may have thus been over-represented in the milnacipran groups 
in these studies. This shows the importance of comparing side-
effect data only within a similar context since the nature of 
the comparator drug can have a considerable inﬂ  uence on the 
adverse effects reported for a new investigational drug.
These two phase III trials in Japanese patients suggest that 
milnacipran has comparable efﬁ  cacy in Japan to that seen in 
European studies. In both areas milnacipran was shown to 
be as effective as traditional reference antidepressants in the 
treatment of depression. Tolerance of milnacipran also appears 
similar in Japan and Europe in spite of the popular belief that 
Japanese patients are more sensitive to adverse effects.
Investigative clinical studies with milnacipran 
in Japan
Formal randomized double-blind controlled trials are 
atypical in Japan and there have been very many more 
investigative clinical studies carried out with milnacipran 
usually at the initiative of the investigators. Although 
many of these studies have methodological limitations 
they have the merit of asking questions and suggesting 
answers outside of the context limited by regulatory 
preoccupations.
Predicting antidepressant response with milnacipran
As with all antidepressants, some patients respond better 
to milnacipran than others. Several studies have tried to 
throw light on factors which may help identify probable 
responders.
In a group of 80 patients treated for 6 weeks with 
milnacipran, a study found that certain polymorphisms 
of the NE transporter genes were related to differences 
in response rates (Yoshida et al 2004a). The presence 
of the T allele of the NET T-182C polymorphism was 
signiﬁ  cantly (p = 0.03) correlated with a greater response 
with milnacipran, whereas the A/A genotype of the NET 
G1287A polymorphism was associated with a slower onset 
of response. In contrast, the presence of the 5-HT transporter 
gene polymorphisms, 5HTTLPR and 5HTTVNTR, had no 
effect on the antidepressant response to milnacipran.
Another study (Shinkai et al 2004) found that responders 
to milnacipran had signiﬁ  cantly lower pretreatment levels 
of plasma 3-methoxy-4-hydroxyphenylglycol (pMHPG) 
compared to non-responders (p = 0.023). In addition, 
improvement in depressive symptoms over 4 weeks, as 
measured by the Hamilton Depression Rating Scale (HAMD), 
was signiﬁ  cantly correlated with increases in pMHPG levels 
(p = 0.03). Responders to paroxetine, on the other hand, had 
signiﬁ  cantly higher pretreatment levels of pMHPG compared 
to non-responders (p = 0.001) with a negative correlation 
between changes in pMHPG levels and improvement of the 
HAMD. This suggests that milnacipran act primarily on the 
noradrenergic system in contrast to paroxetine which acts 
primarily on the serotonergic system. 
A case-control comparison of milnacipran and 
fluvoxamine in 202 outpatients with major depression 
found that the overall response rates were similar for 
both antidepressants. In more severely depressed patients 
(HAMD17 > 19), however, there were significantly more 
responders (≥50% reduction in HAMD17 baseline score) with 
milnacipran (68.9%) than with ﬂ  uvoxamine (46.2%) (p = 0.046) 
(Fukuchi and Kanemoto 2002). In addition patients with 
high scores on the “agitation” and “insomnia” items of the 
HAMD were more likely to respond to milnacipran than to 
Table 1 Comparison of principal adverse events reported in European and Japanese comparative studies of milnacipran vs imipramine 
and milnacipran vs mianserin
  European study    Japanese studies
 Milnacipran  Imipramine  Milnacipran  Imipramine  Milnacipran  Mianserin
Dry  mouth  17% 36%  21% 31% 6% 13%
Constipation  13%  21% 7% 14%  2%  8%
Nausea  7% 4%  7% 2% 6%  1%
Dizziness  5% 9%  7% 14%  2%  6%
Drowsiness  3% 6%  5% 5% 6%  32%
Compiled from data in Tignol et al (1998), Yamishita et al (1995), and Endo et al (1995).Neuropsychiatric Disease and Treatment 2007:3(1) 47
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ﬂ  uvoxamine. These results are similar to those found in a 
double-blind study carried out in Europe in moderately to 
severely depressed (mean HAMD24 = 32.2) patients (Clerc 
et al 2001) which concluded a superior efficacy of 
milnacipran over ﬂ  uvoxamine.
In another study, 80 Japanese patients with major 
depressive disorders were stratiﬁ  ed by severity according to 
their baseline Montgomery-Asberg Depression Rating Score 
(MADRS): “severe” MADRS ≥31 (n = 25); “moderate” 
MADRS = 25–30 (n = 30) and “mild” MADRS = 21–24 
(n = 25) (Sugawara et al 2006). “Severe” and “moderate” 
patients had more melancholia than “mild” patients (17, 6, 
and 1 patient respectively). Milnacipran was administered 
twice daily for 6 weeks at an initial dose of 50 mg/d for 
the ﬁ  rst week and then 100 mg/d. Mean plasma levels of 
milnacipran were similar in the “severe” and “mild” groups 
but significantly higher in the “moderate” group. The 
response rates were 72%, 70%, and 44% in the “severe,” 
“moderate,” and “mild,” categories respectively (Figure 1). 
The differences between “severe” and “mild” and “moderate” 
and “mild” were signiﬁ  cant whereas the difference between 
severe and moderate was not. This study suggests that 
milnacipran may be more effective in treating patients with 
moderate and severe major depression compared to those 
with mild depression.
A retrospective cohort analysis of 159 outpatients treated 
for depression in a Japanese hospital with ﬂ  uvoxamine, 
paroxetine or milnacipran found that older patients (≥50 
years) had a superior response rate with milnacipran than with 
the other antidepressants (Morishita and Arita 2004a). For 
patients under 50 years ﬂ  uvoxamine was the most effective 
antidepressant.
There have been suggestions that female patients may 
respond more favorably than male patients to SSRIs whereas 
the opposite appears to be true for TCAs (Kornstein et al 
2000). In a retrospective cohort analysis of 63 depressed 
patients (34 males, 29 females) treated with milnacipran, 
there was a tendency (p < 0.1) towards a higher frequency 
of improvement among males (83%) than females (62%) 
(Morishita and Arita 2003b). The percent responders was, 
however, signiﬁ  cantly higher among both males and females 
with a ﬁ  rst episode of depression than among those with a 
recurrent episode (Table 2).
Taken together the above studies suggest that depressed 
patients with deﬁ  cient noradrenergic neurotransmission, as 
indicated by MHPG levels and norepinephrine transporter 
polymorphisms, respond particularly well to treatment with 
milnacipran. In addition patients with more severe depression, 
especially those with melancholia, appear to respond better 
to milnacipran than patients with mild depression. There 
are also suggestions for a better response to milnacipran 
among the elderly and in patients with their ﬁ  rst episode of 
depression. These latter observations, however, need to be 
conﬁ  rmed in larger cohorts.
Differences between doses of milnacipran
Although intuitively most clinicians assume that a dose-
response relationship exists for antidepressants it has 
proven difficult to demonstrate this for TCAs (Bollini 
et al 1999) and for SSRIs (Baker et al 2003). Not only are 
the symptoms of depression variable in nature and in their 
pattern of improvement but the pharmacokinetics of many 
antidepressants are complicated by variable absorption, 
active metabolites, and genetic variation in metabolic 
enzymes. For determining the possible existence of a dose-
efﬁ  cacy relationship, milnacipran is close to being an “ideal” 
antidepressant, with an oral bioavailability close to 100%, 
low protein binding, very little metabolism, and an absence 
of active metabolites (Puozzo and Leonard 1996).
The relationship between antidepressant effects and 
plasma levels of milnacipran was investigated in 49 patients 
with major depression (Higuchi et al 2003). Patients were 
treated for 6 weeks with milnacipran at 50 mg/d for the ﬁ  rst 
week and the ﬂ  exibly up to 100 mg/d thereafter. Depressive 
symptoms were evaluated by the MADRS before treatment 
and after 1, 2, 4, and 6 weeks. Nearly 70% of patients 
responded (≥50% decrease in baseline MADRS) and the 
difference between responders and non-responders was 
significant from the first week of treatment. The mean 
plasma milnacipran level of responders (82.0 ± 29.4 ng/ml) 
and non-responders (78.6 ± 23.1 ng/ml) were not, however, 
signiﬁ  cantly different. Furthermore no signiﬁ  cant linear or 
curvilinear relationship was found between the ﬁ  nal MADRS 
score and the plasma levels of milnacipran.
Table 2 Patients responding to milnacipran according to gender 
and frequency of episode
 Men  Women
Overall responders  82.4%# 62.1%
1st episode responders  100%* 85.7%*
Recurrent episode responders  56.3%  42.9%
Responders = decrease ≥50% in baseline HAMD.
#p < 0.1 compared with overall response rate in women.
*p < 0.5 compared with recurrent episode responders of the same sex.
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Another study approached the question of dose-response 
relationship in a different way. The doses of 50 mg/d and 
100 mg/d of milnacipran (both given twice daily) were 
compared in a group of 32 depressed patients. No signiﬁ  -
cant difference was found in the percentage of responders 
at each dose after 8 weeks (Morishita and Arita 2003c). A 
difference in the onset of action was, however, observed. 
The cumulative percentage of responders in the 50 mg/d 
group reached 80% after 6 weeks, while in the 100 mg/d 
group this same level was reached two weeks earlier at 4 
weeks. At the end of 3 weeks treatment there was a signiﬁ  -
cantly greater cumulative percentage of responders in the 
higher dose group.
Two different doses of milnacipran (75 mg/d and 150 
mg/d) were compared in 66 outpatients with major depression 
who were experiencing their ﬁ  rst depressive episode or whose 
previous depressive episode had occurred at least 1 year 
earlier (Kanemoto et al 2004). Patients were randomized and 
titrated to a daily dose of milnacipran of either 75 mg or 150 
mg over 2–3 weeks. This dose was then maintained stable for 
8 weeks. At the end of the study the rates of both response 
(≥50% decrease in HAMD17 from baseline) and remission 
(HAMD17 < 7) were signiﬁ  cantly greater in patients receiving 
milnacipran at 150 mg/d compared with patients receiving 
milnacipran at 75 mg/d (Figure 2). There was no signiﬁ  cant 
difference in the incidence of adverse events.
Thus in spite of the absence of a clear relationship between 
plasma levels and clinical response, there is considerable 
evidence to suggest an enhanced (or accelerated) response 


























Figure 1 Response to milnacipran in patients stratiﬁ  ed by severity. Severity was deﬁ  ned by baseline MADRS; Severe = MADRS ≥ 31; moderate = MADRS 25–30; 
mild = MADRS 21–24; Response = reduction ≥50% of the baseline MADRS; Drawn from data from Sugawara et al (2006).Neuropsychiatric Disease and Treatment 2007:3(1) 49
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Milnacipran in the treatment of different 
types of depression
The clinical trials that led to the registration of milnacipran 
in Japan, as in the rest of the world, were limited to patients 
with “pure” depression. Depression, however, is frequently 
co-morbid with other psychiatric and non-psychiatric 
disorders. Japanese curiosity has led to the experimentation 
of milnacipran in numerous populations of depressed patients 
with various co-morbid disorders or other particularities.
Bipolar depression
All antidepressants have the potential to induce mania (Preda 
et al 2001). Two studies (Table 3) have investigated the use 
of milnacipran in mania.
Although the data are limited these studies suggest that mil-
nacipran is a safe option in the treatment of patients with bipolar 
depression with little on no tendency to induce mania.
Milnacipran in resistant depression
In clinical research resistant depression has a specific 
deﬁ  nition. In clinical practice, however, the term is often used 
to describe the depression in patients who have not obtained a 
satisfactory response from an antidepressant treatment. Used 
in this sense, the effect of milnacipran in resistant depression 
has been the subject of a small study in Japan (Table 3) which 
suggests that milnacipran can be useful in some patients 
resistant to other antidepressants. Full controlled trials are, 
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Figure 2 Response to milnacipran at different doses. 66 patients were randomized and titrated to a daily dose of milnacipran of either 75 mg or 150 mg over 2–3 weeks; 
This dose was then maintained stable for 8 weeks; 25 and 26 patients, respectively, completed the study in the 75 mg/d and 150 mg/d groups; Response = reduction ≥50% in 
HAMD17 from baseline; Remission = HAMD17 <7; Drawn from data from Kanemoto et al (2004).Neuropsychiatric Disease and Treatment 2007:3(1) 50
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Depression following brain trauma or stroke
Mild to moderate traumatic brain injury is often followed by 
depression (Alderfer et al 2005). Depression is also common 
after stroke and has numerous similarities with depression 
following brain trauma (Gupta et al 2002). Studies with 
TCAs and SSRIs have suggested that an antidepressant 
with a noradrenergic component is required for the best 
efﬁ  cacy in this condition. Nortriptyline, for example, has 
been shown to be superior to the SSRI ﬂ  uoxetine in a large 
double-blind, placebo-controlled trial (Robinson et al 2000). 
Studies with milnacipran in post-trauma and post-stroke 
depression (Table 3) suggest that milnacipran may be 
particularly effective. One study which measured cognitive 
impairment (Table 3) found that milnacipran produced a 
signiﬁ  cantly greater improvement than no treatment. Thus 
milnacipran may be effective in relieving the depression 
often associated with brain trauma or stroke without any 
negative impact on functional recovery. Unfortunately, 
however, the antidepressant does not appear to accelerate 
rehabilitation. 
Depression in Parkinson’s disease
Depression is frequently co-morbid with Parkinson’s disease 
with anhedonia and apathy as the principal symptoms (Okun 
and Watts 2002). Both TCAs and SSRIs have been used 
to treat depression associated with Parkinson’s disease. 
The poor tolerance of the TCAs and the tendency of SSRI 
to worsen motor function have stimulated the search for 
other therapeutic options (Richard and Kurlan 1997). Some 
studies have found that compounds stimulating principally 
noradrenergic neurotransmission are better able to improve 
depression in parkinsonian patients (Andersen et al 1980; 
Narabayashi et al 1991).
A pilot study (Table 3) showed a reduction in 
depressive symptoms, especially anhedonia and apathy 
with milnacipran.
In addition, two cases have been reported (Takahashi 
et al 2005) of parkinsonian patients with depression with 
an insufﬁ  cient antidepressant response to SSRIs who were 
switched to milnacipran and achieved complete remission. 
These cases suggest that milnacipran is a potentially 
useful treatment of depression in patients with Parkinson’s 
disease, which is well tolerated and has no adverse effects 
on motor function and does not interact  pharmacokinetically 
with parkinsonian treatment. There is a suggestion that it 
may usefully replace SSRI treatment where this does not 
lead to full remission.
Depression in schizophrenia
Over 25% of schizophrenic patients manifest depressive 
symptoms (Siris 1991), which predict a poor overall outcome 
of treatment. Because of its lack of potential for drug interaction 
(Puozzo and Leonard 1996), milnacipran has an advantage 
in treating depressive symptoms in schizophrenic patients 
already receiving antipsychotic medication. A pilot study in 
7 schizophrenic patients with depressive symptoms (Table 3) 
showed a marked response in some patients but no response in 
others. Milnacipran was well tolerated and none of the patients 
had any aggravation of their psychotic symptoms.
Depression in Alzheimer’s disease
The prevalence of depression in Alzheimer’s disease patients 
varies from 5% to nearly 45% depending on the criteria 
used (Vilalta-Franch et al 2006). The results of a pilot study 
(Table 3) result suggest that milnacipran may be a potentially 
useful treatment of depression in patients with Alzheimer’s 
disease. In addition since Alzheimer’s patients are frequently 
polymedicated, milnacipran’s low potential for drug–drug 
interactions is another advantage in this patient population.
Depression induced by treatment with interferon
Interferons are important antiviral and neoplastic agents 
but one of the inconveniences of interferon therapy is the 
depression that they induce in certain patients (Trask et al 
2000). Direct intracebroventricular injection of interferon-α 
in rats has been shown to cause a dose-related decrease in the 
levels of both 5-HT and NE (Kamata et al 2000) in the frontal 
cortex, which suggests that milnacipran could be effective 
in relieving interferon-induced depression. A case report of 
the use of milnacipran (Table 3) showed the total reversal of 
interferon-induced depression after 4 weeks of treatment.
Menopausal depression and premenstrual 
dysphoric disorder 
The onset of menopause is often accompanied by a depres-
sive state in women, although the mechanism involved is 
poorly understood. Premenstrual dysphoric disorder (PMDD), 
which has an estimated prevalence of 2%–9% in menstruating 
women (Yonkers 1997) is usually treated with SSRIs. Certain 
women, however, are intolerant of the digestive side-effects 
of these drugs and alternatives are frequently sought.
The duration of immobility of male rodents during the 
forced swimming test is a well known measure of a depression-
like state. In a proposed model of menopausal depression, the 
duration of immobility was signiﬁ  cantly increased in female 
mice following bilateral ovariectomy (Bekku and Yoshimura Neuropsychiatric Disease and Treatment 2007:3(1) 51
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Table 3 Effect of milnacipran in the treatment of different types of depression
Bipolar   Retrospective cohort   Paroxetine n = 79   Milnacipran n = 68   Morishita and  
depression  analysis of depressed   ~12% bipolar  ~12% bipolar  Arita (2004b)
  (uni or bipolar) patients  Induction of hypomania   Induction of hypomania 
    7/79 (8.9%)  1/68 (1.5%)
  Pilot study in 9 bipolar   Milnacipran + pre-existing treatments (lithium,   Yamada 2001a
  depressed  clonazepam, valproate or carbamazepine)
   8/9  Efﬁ  cacy without manic activation Prolongation of 
    asymptomatic period in 6 rapid cycling patients
Resistant   8 depressed females resistant   Milnacipran as add-on therapy (30–100 mg/d)  Yamada 2001b
depression  to antidepressants (doses   1/8 drop-out (adverse effects)7/8 successful response (mood 
  equivalent to 150 mg/d   and psychomotor retardation most notably improved)
 imipramine)  administered 
  from 4 to 17 months
Depression   6-week open pilot study in   Milnacipran (30–50 mg/d)    Kanetani et al 
following   10 patients with depression   1/10 drop-out (non-serious side-effects)   2003
brain trauma   occurring following brain trauma  6/10 responders
   4/10  remissions 
    In all patients: improvement in cognitive function
Post-stroke   12 patients with major or  Milnacipran (60–50 mg/d) for 6 weeks   Kimura et al 
depression  minor depression (onset   2/12 dropped out     2002
  subsequent to a cerebral   3/12 experienced non-serious side-effects but continued 
  infarction or hemorrhage)  the study 7/12 remitted
 
  18 patients with depression   Milnacipran 30–60 mg/day (n = 10) Antidepressant   Sato et al 
  occurring within 3 months   treatment refusal (n = 8)    2006
  of a stroke. Open comparison  Improvement in cognitive function (MMSE score) 
    Milnacipran > no treatment (p = 0.034). No difference 
    between the two groups for changes in depression.
 
  11 patients in a rehabilitation   Milnacipran given for 3 months    Yamakawa et al
  hospital compared to  Greater improvement of depression (Zung) in milnacipran   2005 
  untreated controls  group but similar rehabilitation in both groups
Depression in   12-week pilot study   Milnacipran (30–60 mg/d)    Maruyama 
Parkinson’s   in 8 patients  1/8 patient withdrew (palpitations and agitation)  2003
disease    7/8 patients reduced depressive symptoms (especially 
    anhedonia and apathy) from week 4
Depression in   7 schizophrenic patients   Milnacipran in addition to both traditional and atypical   Nakanishi et al 
schizophrenia  with depressive symptoms   antipsychotics     2004
   Depressive  symptoms 
    3/7 marked improvement
    1/7 slight improvement
   3/7  unchanged
  55-year-old woman with   Milnacipran + olanzapine     Sugawara et al 
  delusional depression   Resolution of all symptoms    2005
 with  anorexia
Depression in   Open-labeled study in   Milnacipran    Mizukami et al 
Alzheimer’s   11 Alzheimer’s patients   Within 12 weeks    2006
disease   with major depressive   10/11 responders
  symptoms   8/11 sustained remissions with considerable improvement in 
   global  functioning 
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Table 3 Continued
2005). Chronic treatment with estradiol prevented this 
increased immobility. Chronic treatment with milnacipran 
as well as imipramine and ﬂ  uvoxamine signiﬁ  cantly reduced 
the duration of the immobility. These results suggest that 
the forced swim test in ovariectomized female mice may 
be a useful animal model for menopausal depression and 
that milnacipran is likely to be as effective in this type of 
depression as the TCAs or the SSRIs.
Clinical support of this suggestion has come from the 
successful treatment of PMDD by milnacipran of 3 women 
who could not tolerate SSRI treatment (Table 3).
Boosting the action of milnacipran
Low energy, lack of motivation and fatigue are residual 
symptoms often seen in patients with only a partial response 
to antidepressants (Nierenberg and DeCecco 2001). The 
biological basis of these symptoms in depression is unclear 
but some reports suggest that a persistent decrease in brain 
NE and dopamine may be involved (Schmidt et al 2001). 
A treatment that enhances neurotransmission of these two 
monoamines is likely to boost energy and reduce fatigue in 
patients with these symptoms of depression. Two cases have 
been reported of the successful combined use of milnacipran 
and the dopamine agonist, cabergoline, to achieve complete 
remission in patients whose residual symptoms, including 
energy loss and fatigue, were refractory to previous treatments 
(Takahashi et al 2003). In both cases treatment with SSRIs 
achieved only limited response. Switching to milnacipran 
produced greater response but not complete remission with 
low energy, lack of motivation and fatigue remaining as 
the principal residual symptoms. Supplementation with 
lithium or thyroid hormone was without effect. The addition, 
however, of the dopamine receptor agonist, cabergoline, 
achieved full sustained remission in both cases.
Lithium is a standard augmentation therapy for 
antidepressants (see for example Moret 2005). The 
administration of lithium to rats signiﬁ  cantly increased basal 
levels of extracellular 5-HT in the medial prefrontal cortex 
(Kitaichi et al 2005b). Milnacipran combined with lithium 
treatment resulted in a greater increase in extracellular 
5-HT, as well as increases in the levels of NE and dopamine 
which were greater than with milnacipran alone (Kitaichi 
et al 2005b). This suggests that lithium augmentation might 
increase the antidepressant effect of milnacipran while 
respecting the balance of effects on the monoamines.
A pilot study using the treatment algorithm established 
by the Japanese Psychopharmacology Algorithm Project 
(JPAP) (Kobayashi et al 2004) found that the combination of 
lithium with milnacipran was the most effective second-line 
therapy with 4 out of 4 patients responding to a combination 
of milnacipran and lithium after failure of a ﬁ  rst-line therapy 
with a SSRI. Although more cases need to be investigated, the 
    2/11 mild hypomania 
    1/11 daytime somnolence (problems resolved after reducing 
    the daily dose of milnacipran) 
    No negative effects on cognitive function.
Depression   A 71-year-old man with cancer,  No relief of depressive symptoms with reduction of   Yoshida et al 
induced by   treated by interferon-α2A,   interferon dose     2003
treatment with   complained of depressed   Only partial efﬁ  cacy with trazodone 
interferon  mood, lassitude and irritability.  Progressive replacement of trazodone by milnacipran
    Decline of depressive symptoms. After 4 weeks milnacipran 
    treatment, disappearance of symptoms with no resurgence 
    after interferon injections.
Depression in   A terminally ill cancer patient   Milnacipran     Sato et al 2004
cancer patients  with major depressive disorder   Rapid improvement in symptoms after 1–2 weeks.
Menopausal   3 women with PMDD not   Milnacipran at 30 mg/d (15 mg twice daily) in the luteal phase   Yamada and
depression and   tolerating SSRI treatment  2/3 improved     Kanba 2005
premenstrual     1/3 improved when dose increased to 60 mg/d 
dysphoric    (30 mg twice daily)
disorder 
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combination of lithium and milnacipran should be considered 
a potentially useful second-line therapy.
Typically antidepressants take at least 4 weeks to provide 
signiﬁ  cant beneﬁ  t. An open pilot study of 21 depressed patients 
tested the effect of co-administering the SSRI, ﬂ  uvoxamine, 
with milnacipran. The cumulative percentage of responders 
reached over 80% within 3 weeks with the combined treatment 
(Morishita and Arita 2005a). There were no patients under 
monotherapy for comparison in this study but an earlier 
retrospective cohort analysis of 206 out-patients found that 
the cumulative percentage of responders receiving milnacipran 
alone reached 80% within 4 weeks, whereas for patients treated 
with ﬂ  uvoxamine or paroxetine it took 6 weeks to achieve this 
same cumulative percentage of responders (Morishita and 
Arita 2003a). This study suggests that a more rapid onset of 
action may possibly be achieved by the use of a combination 
of antidepressants with different mechanisms of action. A 
replication is obviously necessary.
Five patients with major depression without psychotic 
features who responded only partially to milnacipran alone, 
even at doses of up to 300 mg/d, were co-administered the 
atypical antipsychotic, risperidone (usually at 1 mg/d) (Tani 
et al 2004). Rapid improvements of depressive symptoms 
occurred within 1–4 days. In all cases the patients subsequently 
achieved full remission on the combination therapy.
Milnacipran in disorders other 
than depression
Anxiety
Most antidepressants have been found to be active in a 
number of disorders in addition to depression. The SSRIs 
have been the most investigated in this respect and it is 
generally accepted that most (if not all) SSRIs are effective in 
the whole spectrum of anxiety disorders (Vaswani et al 2003). 
The SNRI venlafaxine has also been extensively studied in 
anxiety (Silverstone 2004; Stahl et al 2005).
A small open study of 12 patients investigated the efﬁ  cacy 
of milnacipran in generalized anxiety disorder (Tsukamoto 
et al 2004). Two patients discontinued because of adverse 
effects (nausea). All 10 of the patients completing the study were 
markedly improved with a reduction of their Hamilton anxiety 
(HAMA) scores of at least 70% over the 8-week study.
Taijin-Kyofusho (TKS) is a distinct form of social anxiety 
disorder speciﬁ  c to Japanese culture in which patients suffer 
from intense fear that his or her body or its functions are 
offensive to other people. A 12-week open trial examined 
the effect of milnacipran in 12 patients with TKS with social 
anxiety disorder (Nagata et al 2003). Six of the 11 patients 
who completed therapy responded (“much improved” or 
“very much improved” on the Clinical Global Impression 
(CGI)—Improvement scale). The mean Liebowitz Social 
Anxiety Scale (LSAS) score and TKS offensive anxiety also 
showed statistically signiﬁ  cant reductions. 
In a follow-up study 16 patients with TKS were treated 
with milnacipran for 12 weeks (Nagata et al 2005). Six 
patients discontinued in the ﬁ  rst few days of treatment 
because of nausea. Of the 10 who completed the study 7 
responded (≤2 on the CGI-severity scale at endpoint). TKS 
offensive anxiety (fear of offending other people), which 
was assessed by an original scale developed by the authors, 
was signiﬁ  cantly reduced. In addition patients’ insight and 
emotional coping strategies were signiﬁ  cantly improved. 
Although conﬁ  rmation from placebo controlled trials is still 
lacking, these studies suggest that milnacipran may be helpful 
in treating this speciﬁ  c type of social anxiety.
Pain
TCAs are the antidepressants most commonly used in the 
treatment of chronic pain. The effect of these antidepressants 
on both NE and 5-HT is thought to be a key factor in their 
effect on chronic pain (Barkin and Fawcett, 2001) since 
SSRIs are not particularly helpful (Briley 2004). SNRIs such 
as milnacipran that can be seen as “well-tolerated TCAs” are 
thus an obvious therapeutic option to test in chronic pain.
Glossodynia is an orolingual chronic pain syndrome, 
which is characterized by a spontaneous burning sensation 
mainly affecting the tongue with clinically normal oral 
mucosa. Eleven patients with glossodynia and no history of 
signiﬁ  cant psychiatric illness were treated with milnacipran 
on an open, variable dose, basis for 6 weeks (mean ﬁ  nal dose 
58.6 mg/d). Ten patients completed the study. Eight of these 
reported decreased pain intensity, 6 had a decrease of more 
than 50%, and 4 reported negligible pain at the end of the 
study. For most patients the maximal beneﬁ  t was achieved 
within the ﬁ  rst week of treatment (Toyofuku 2003). Another 
case, reported by Kamata et al (2003), was a 72-year-old 
housewife who suffered from glossal pain for 32 months 
although no tongue, nose, or throat abnormality was found. 
No depressive symptoms were noted. Non-steroidal anti-
inﬂ  ammatory drugs and diazepam were tried without success. 
These treatments were stopped and the patient was started 
on milnacipran at 50 mg/d. The pain subsided markedly Neuropsychiatric Disease and Treatment 2007:3(1) 54
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within 2 weeks and after a month the patient was virtually 
pain-free.
There have been a number of case reports of successful 
treatment of different types of chronic pain with milnacipran. 
Two cases of post-herpetic neuralgia improved with 
milnacipran have been independently reported (Shimamoto 
et al 2002; Utsunomiya et al 2002). In another case in a 
patient without depressive symptoms, milnacipran brought 
about a drastic improvement in refractory severe chronic pain 
in the left lateral femoral region whose severity the patient 
evaluated, on a VAS scale, at 94% (Kito et al 2005).
A fuzzy logic analysis of the verbal expression of pain 
into “surface” and “deep” pain (Morishita and Arita 2005b) 
was used to study a series of 5 patients with depression with 
painful symptoms. The authors found that the pain associated 
with depression was “deep” pain and that milnacipran was 
effective in relieving this “deep” pain in all of these patients. 
Pain arising from orthopedic causes including osteoarthritis 
has also been successfully treated with milnacipran. A series 
of 15 patients with a primary diagnosis of orthopedic pain, 
including degenerative spondylosis, lumbar spinal canal 
stenosis and osteoarthritis of the knee with symptoms which 
included low back pain, ischialgia, intermittent claudication 
and lower limb arthralgia were administered milnacipran, at 
50 mg/d, for 8 weeks. Twelve of the 15 patients completed 
the study. Of these, symptomatic improvement was seen in 
ten patients while in four patients pain was reduced by more 
than 80%. Symptoms remained unchanged in the other two 
patients (Tanikawa 2002). 
A 39-year-old woman suffering from an extremely 
painful temporomandibular disorder which developed into 
a generalized ﬁ  bromyalgia was treated with milnacipran, at 
a dose of 30 mg/d increasing progressively over 6 months 
to 120 mg/d. Dose and time-dependent improvements were 
observed in occlusal discomfort, generalized pain and the 
associated symptoms of sleep disorder, chronic fatigue, 
stiffness, numbness, and depressed mood. The treatment 
enabled the rehabilitation of the patient with a major 
improvement in her quality of life (Toyofuku and Miyako 
2004).
An open-label clinical trial has also shown milnacipran to 
be effective in relieving pain and other symptoms in patients 
with ﬁ  bromyalgia syndrome with co-morbid depressive 
symptoms (Nagaoka et al 2004). The efﬁ  cacy of milnacipran 
in ﬁ  bromyalgia has subsequently been conﬁ  rmed in a double-
blind placebo-controlled trial in the USA (Gendreau et al 
2005).
Treatment of 5 non-depressed outpatients, who had 
been suffering from chronic pain for at least 3 months, 
with milnacipran has been reported by Kamata et al (2004). 
Chronic pain was assessed using a 100 mm visual analog 
scale (VAS) before and 12 weeks after the start of the 
milnacipran treatment or at the time the drug was stopped. 
The mean duration of pain before treatment was 17.8 months 
and the mean baseline pain intensity on the VAS was 
88.2%. Milnacipran treatment was started at 50 mg/d and 
increased ﬂ  exibly to 150 mg/d. The mean dose at the end 
of treatment was 85.0 mg/d. At the end of the treatment the 
mean pain intensity on the VAS was 61.2%. Three of the 5 
patients showed marked improvement (decrease in VAS > 
75%). One patient showed moderate improvement (42.0% 
decrease in VAS). The ﬁ  fth patient experienced nausea and 
discontinued treatment after 4 weeks at which time his VAS 
had decreased by 14.3%.
Although most of the data come from case reports and 
small open studies, there is an accumulating mass of data 
to suggest that milnacipran may be helpful in the treatment 
of chronic pain both associated with and independent of 
depression (Briley 2004). In particular the conﬁ  rmation, 
in a placebo-controlled trial, of efﬁ  cacy of milnacipran 
in ﬁ  bromyalgia (Gendreau et al 2005) should encourage 
the follow up of many of these studies by larger and more 
rigorously designed trials.
Memory
A single report has suggested that milnacipran may be useful 
in certain syndromes involving memory dysfunction such 
as Korsakoff’s syndrome, a chronic memory disorder with 
both retrograde and anterograde amnesia. Noradrenergic, 
serotonergic, and cholinergic dysfunctions have been 
suggested to be involved in this syndrome (McEntee and 
Mair 1990).
A single case of memory improvement following treatment 
with milnacipran of a patient with Korsakoff’s syndrome has 
been reported (Numata et al 2005). A 48-year-old woman 
was diagnosed with non-alcoholic Korsakoff’s syndrome 
following herpes simplex encephalitis. Carbamazepine was 
administered for emotional instability and inappropriate 
behavior and resulted in a dramatic improvement of these 
symptoms but had no effect on her memory. Milnacipran 
(50–100 mg/d) was prescribed in addition to carbamazepine to 
improve memory disturbances. After 1 month of milnacipran 
treatment, memory performance, as measured with the 
Hasegawa dementia scale and the Benton visual retention test, Neuropsychiatric Disease and Treatment 2007:3(1) 55
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were signiﬁ  cantly improved permitting the patient to leave 
hospital. Further studies are clearly warranted in this area.
Tolerability
As already mentioned, the tolerability of milnacipran in 
Japanese patients is, in general, similar to that observed in 
Europe and other parts of the world. No “Japan-speciﬁ  c 
adverse events” have ever been reported. Considering the 
number of Japanese patients treated with milnacipran and 
the popularity of case reports in Japan there have been very 
few case reports of intolerability of milnacipran. The four 
published case reports brought to light by a Medline search 
carried out in July 2006 are summarized in Table 4.
The principal adverse effects seen with milnacipran in 
Japan, as in Europe, can be explained by the pharmacology 
of the mechanism of action of milnacipran, namely the poten-
tiation of noradrenergic and serotonergic neurotransmission 
in the brain and the periphery. As such the adverse effects 
are invariably reversible and respond to dose reduction or 
withdrawal of the drug.
Conclusions
Well over half of the publications concerning milnacipran 
over the last 5 years have originated from Japan according to 
a Medline search. This is probably an underestimate since it 
excludes most publications in Japanese and many publications 
in minor Japanese journals that are not covered by Medline.
Although most of the clinical studies are small and 
many of them lack rigorous protocols, they have the merit 
of exploring many areas of potential interest for a new 
antidepressant drug including its use in patients with co-
morbid disorders and disorders other than depression.
The studies reviewed here suggest that patients with 
serotonergic and, more importantly, noradrenergic deﬁ  cits 
and those with more severe depressive symptoms are likely 
to respond best to milnacipran. Milnacipran is likely to be 
active in anxiety, especially generalized social anxiety. The 
probable activity in chronic pain disorders has already been 
conﬁ  rmed by controlled studies in ﬁ  bromyalgia.
As a well-tolerated antidepressant with a very low risk 
of drug–drug interactions, milnacipran would be expected 
to be useful in depressed patients with various co-morbid 
disorders. Numerous and varied reports from Japanese 
clinicians indeed suggest this.
Finally the very few case reports of adverse events that have 
been published conﬁ  rm the good tolerability of milnacipran 
predicted by its preclinical proﬁ  le and early clinical trials. 
There is no evidence of any differences in efﬁ  cacy or adverse 
events between Japanese patients and those from other parts of 
the world. It would therefore appear legitimate to extrapolate 
from the Japanese experience to all other parts of the world.
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